NCT05618613View on ClinicalTrials.gov

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions
Breast Cancer
Interventions
DRUG

Elacestrant

Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.

DRUG

Onapristone

Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.

Trial Locations (3)

37203

Sarah Cannon Research Institute, Nashville

60099

Cancer Treatment Centers of America - Midwestern Regional Center, Zion

85338

Cancer Treatment Centers of America - Western Regional Medical Center, Phoenix

Sponsors
All Listed Sponsors
lead

Context Therapeutics Inc.

INDUSTRY

NCT05618613 - Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter